TY - JOUR A1 - Seefried, Lothar A1 - Mueller-Deubert, Sigrid A1 - Schwarz, Thomas A1 - Lind, Thomas A1 - Mentrup, Birgit A1 - Kober, Melanie A1 - Docheva, Denitsa A1 - Liedert, Astrid A1 - Kassem, Moustapha A1 - Ignatius, Anita A1 - Schieker, Matthias A1 - Claes, Lutz A1 - Wilke, Winfried A1 - Jakob, Franz A1 - Ebert, Regina T1 - A small scale cell culture system to analyze mechanobiology using reporter gene constructs and polyurethane dishes N2 - Mechanical forces are translated into biochemical signals and contribute to cell differentiation and phenotype maintenance. Mesenchymal stem cells and their tissuespecific offspring, as osteoblasts and chondrocytes, cells of cardiovascular tissues and lung cells are sensitive to mechanical loading but molecules and mechanisms involved have to be unraveled. It is well established that cellular mechanotransduction is mediated e.g. by activation of the transcription factor SP1 and by kinase signaling cascades resulting in the activation of the AP1 complex. To investigate cellular mechanisms involved in mechanotransduction and to analyze substances, which modulate cellular mechanosensitivity reporter gene constructs, which can be transfected into cells of interest might be helpful. Suitable small-scale bioreactor systems and mechanosensitive reporter gene constructs are lacking. To analyze the molecular mechanisms of mechanotransduction and its crosstalk with biochemically induced signal transduction, AP1 and SP1 luciferase reporter gene constructs were cloned and transfected into various cell lines and primary cells. A newly developed bioreactor and small-scale 24-well polyurethane dishes were used to apply cyclic stretching to the transfected cells. 1 Hz cyclic stretching for 30 min in this system resulted in a significant stimulation of AP1 and SP1 mediated luciferase activity compared to unstimulated cells. In summary we describe a small-scale cell culture/bioreactor system capable of analyzing subcellular crosstalk mechanisms in mechanotransduction, mechanosensitivity of primary cells and of screening the activity of putative mechanosensitizers as new targets, e.g. for the treatment of bone loss caused by both disuse and signal transduction related alterations of mechanotransduction. KW - Bioreaktor KW - Mechanical strain KW - mechanosensitive reporter KW - gene constructs KW - bioreactor Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68099 ER - TY - JOUR A1 - Jobs, Alexander A1 - Vonthein, Reinhard A1 - König, Inke R. A1 - Schäfer, Jane A1 - Nauck, Matthias A1 - Haag, Svenja A1 - Fichera, Carlo Federico A1 - Stiermaier, Thomas A1 - Ledwoch, Jakob A1 - Schneider, Alisa A1 - Valentova, Miroslava A1 - von Haehling, Stephan A1 - Störk, Stefan A1 - Westermann, Dirk A1 - Lenz, Tobias A1 - Arnold, Natalie A1 - Edelmann, Frank A1 - Seppelt, Philipp A1 - Felix, Stephan A1 - Lutz, Matthias A1 - Hedwig, Felix A1 - Borggrefe, Martin A1 - Scherer, Clemens A1 - Desch, Steffen A1 - Thiele, Holger T1 - Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA‐ADHF‐DZHK10 trial JF - ESC Heart Failure N2 - Aims Treating patients with acute decompensated heart failure (ADHF) presenting with volume overload is a common task. However, optimal guidance of decongesting therapy and treatment targets are not well defined. The inferior vena cava (IVC) diameter and its collapsibility can be used to estimate right atrial pressure, which is a measure of right‐sided haemodynamic congestion. The CAVA‐ADHF‐DZHK10 trial is designed to test the hypothesis that ultrasound assessment of the IVC in addition to clinical assessment improves decongestion as compared with clinical assessment alone. Methods and results CAVA‐ADHF‐DZHK10 is a randomized, controlled, patient‐blinded, multicentre, parallel‐group trial randomly assigning 388 patients with ADHF to either decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment or clinical assessment alone. IVC ultrasound will be performed daily between baseline and hospital discharge in all patients. However, ultrasound results will only be reported to treating physicians in the intervention group. Treatment target is relief of congestion‐related signs and symptoms in both groups with the additional goal to reduce the IVC diameter ≤21 mm and increase IVC collapsibility >50% in the intervention group. The primary endpoint is change in N‐terminal pro‐brain natriuretic peptide from baseline to hospital discharge. Secondary endpoints evaluate feasibility, efficacy of decongestion on other scales, and the impact of the intervention on clinical endpoints. Conclusions CAVA‐ADHF‐DZHK10 will investigate whether IVC ultrasound supplementing clinical assessment improves decongestion in patients admitted for ADHF. KW - acute decompensated heart failure KW - inferior vena cava KW - congestion KW - NT‐proBNP KW - ultrasound Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212692 VL - 7 IS - 3 SP - 973 EP - 983 ER - TY - THES A1 - Lutz, Jakob T1 - Prospektive Validierung des Erlangen Index als präoperatives geriatrisches Assessment zur Beurteilung des postoperativen Outcome großer urologischer Eingriffe T1 - Prospective validation of the Erlangen Index as a preoperative geriatric assessment for the evaluation of the postoperative outcome of major urologic surgery N2 - Die Gesellschaft altert und es erhalten vermehrt geriatrische Patienten radikale urologische Eingriffe. Alte Patienten haben im Rahmen derartiger Operationen ein erhöhtes Risiko sowohl für Komplikation, verschlechtertes funktionelles Outcome und Mortalität. Da alte Patienten dennoch von den Operationen profitieren können und diese auch weitgehend sicher bei diesen durchgeführt werden können, gilt es das geriatrische Patientenklientel in Bezug auf ihre Konstitution präoperativ genauer zu evaluieren. Die Erlanger Pilotstudie, an die sich vorliegende Arbeit anlehnt, hat dazu einen Index für Patienten ≥ 70 Jahre mit geplanter Prostatektomie, Nephrektomie und Zystektomie entwickelt, der sowohl das postoperative funktionelle Outcome nach 30 bzw. 180 Tagen, wie auch die Mortalität, nicht aber Komplikationen signifikant korrekt vorhersagen konnte. Ziel vorliegender Arbeit war es, die Prädiktivität des Erlangen Index hinsichtlich dieser vier Endpunkte in einer prospektiv angelegten Studie mit n=46 Patienten ≥ 65 Jahre am Universitätsklinikum Würzburg zu validieren. Es sollte dabei im Speziellen die in der Erlanger Pilotstudie erfasste gute Prädiktivität des Erlangen Index für das funktionelle Outcome nach 180 Tagen überprüft werden. In dieser Arbeit zeigte sich der Erlangen Index prädiktiv für das funktionelle Outcome nach 180 Tagen. Für die anderen Endpunkte konnte keine Prädiktivität des Erlangen Index festgestellt werden. Durch vorliegende Studie konnte die schlechte Prädiktion der Komplikationen durch den EI bestätigt werden. Anders als in der Pilotstudie war der Erlangen Index in vorliegender Studie zur Vorhersage des funktionellen Outcome nach 30 Tagen und der Mortalität nicht geeignet. Bei Betrachtung der Untergruppen nach Art der Operation zeigte der EI starke Korrelationen für die Prädiktion des funktionellen Outcome nach 180 Tagen in den Gruppen der Patienten nach Prostata- und Harnblasenoperation. Die Ergebnisse decken sich somit nur teilweise mit den Ergebnissen aus der Pilotstudie in Erlangen, in der der Erlangen Index bzgl. des funktionellen Outcome nach 180 Tagen die größte Korrelation in der Untergruppe der Patienten nach Nephrektomie zeigte. Der Index erwies sich als schnell durchführbares Assessment, das wenig Personal erfordert. Es ist weiter zu prüfen, ob sich durch Anwendung dieses Assessment tatsächlich Änderungen im klinischen Therapieregime ergeben bzw. ob sich die Modifizierungen der Therapie auch in einem verbesserten Outcome der Patienten auswirken. N2 - The society is aging steadily and there is a rising number of geriatric patients receiving major urologic surgery. Older patients tend to be more in danger of postoperative complications, deteriorated functional outcome and mortality undergoing these major surgical interventions. Since some older patients still may benefit from radical treatments and since these surgical treatments can potentially be performed safely also in older people, their functional constitution should be assessed prior to surgery. In order to tackle this goal the Erlangen pilot trial, which our trial refers to, developed an index for people older than 70 years undergoing prostatectomy, nephrectomy and cystectomy. This Index proved to be suitable to predict the functional outcome atfer 30 and 180 days, as well as the mortality significantly, whereas complications couldn`t be predicted properly. In this prospective trial, comprising n=46 patients ≥ 65 Jahre, we aimed to validate the predictivity of the Erlangen Index according to these 4 endpoints, especially focussing on the functional outcome after 180 days, for which Erlangen Index was shown to be predictive in the pilot trial. In our validation trial the Erlangen Index was shown to be predicitve for the functional outcome after 180 days. However, for the other three endpoints there were no significant findings. Hence in this trial we were able to confirm the low predictivity of Erlangen Index for complications. In contrast to the pilot trial, in this very trial the Erlangen Index was shown not to be predicitve for functional outcome after 30 days, as well as mortality. Taking a look at the subgroups the Erlangen Index showed strongest correlation in predicting the functional outcome after 180 days in the subgroup of patients undergoing prostatectomy and cystectomy. According to that our findings only seem to match partially with the findings of the pilot trial, where Erlangen Index showed strongest correlation in predicting the functional outcome after 180 days in the subgroup of patients with nephrectomy. The Erlangen Index showed to be a quick and feasible tool, requiring only little staff. It still has to be investigated, whether the use of geriatric assessments will eventually lead to changes in therapeutic regimen and whether therapeutical modifications will finally end up in an improved functional outcome of patients. KW - Operation KW - Urologie KW - Geriatrie KW - Index KW - Gebrechlichkeit KW - Assessment KW - Frailty KW - Outcome Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-351686 ER -